Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma
Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.
Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma (FL).
There is no clear way to distinguish which patients will do poorly after treatment, and there’s also no biomarkers to determine the response, says Casulo. With a plethora of options available, a physician might select therapy based on when the patient recurs; if a patient recurred early, those patients can be treated more aggressively, but an older patient might need to be considered for a more gentle approach.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
